Articles by tag: mrna-cancer-vaccine

mRNA vaccine against glioblastoma: 42% survival in phase 2

Personalized mRNA vaccine showed 42% 18-month recurrence-free survival in glioblastoma. Learn details of the breakthrough JAMA study and prospects of the method.

First mRNA vaccine against lung cancer from BioNTech

BioNTech's personalized mRNA therapy against NSCLC is on the way. The vaccine reduces the risk of melanoma recurrence by 49%. Learn about the future of personalized oncology.